Overview
Sweden cancer therapy device maker's Q1 sales fell 72% yr/yr due to partner alignment talks
Q1 operating profit declined, reflecting lower revenue, not higher expenses
Company secured SEK 23 mln purchase orders for Prism business after quarter end
Outlook
CLS expects 2026 revenue to show strong double-digit growth versus 2025, with H2 weighting
Company has secured purchase orders of about SEK 23 mln for the neurosurgery Prism business
CLS now expects positive cash flow from Q1 2028, updating previous guidance of Q4 2026
Result Drivers
PARTNER ALIGNMENT TALKS - Sales of Prism products to neurosurgery partner were temporarily impacted by ongoing alignment discussions, leading to lower Q1 revenue
CLINICAL MOMENTUM - Continued installations and procedure growth in U.S. neurosurgery market reflected underlying clinical and commercial momentum
COST CONTROL - Decline in operating profit reflected lower revenue, not increased expenses, as CLS maintained strict cost control and improved operational efficiency
Company press release:
Key Details
Metric
Q1 Sales
Beat/Miss
Actual
SEK 1.30 mln
Consensus Estimate
Analyst Coverage
Wall Street's median 12-month price target for Clinical Laserthermia Systems AB is SEK9.00, about 86.3% above its May 11 closing price of SEK4.83
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .